Raporty finansowe: Rachunek zysków i strat
BAY (BAYER)
122.00+10.86(+9.77%)
BAYER AG
TENDENCJE NEGATYWNE
Przychody ze sprzedaży: spadek o 12.96% r/r |
Zysk ze sprzedaży: spadek o 4.68% r/r |
Zysk operacyjny (EBIT): spadek o 91.91% r/r |
EBITDA: spadek o 27.07% r/r |
Zysk przed opodatkowaniem: spadek o 132.18% r/r |
Zysk netto: spadek o 165.47% r/r |
2010/Q4 (gru 10) | 2011/Q4 (gru 11) | 2012/Q4 (gru 12) | 2013/Q4 (gru 13) | 2014/Q4 (gru 14) | 2015/Q4 (gru 15) | 2016/Q4 (gru 16) | 2017/Q4 (gru 17) | 2018/Q4 (gru 18) | 2019/Q4 (gru 19) | 2020/Q4 (gru 20) | 2021/Q4 (gru 21) | 2022/Q4 (gru 22) | 2023/Q4 (gru 23) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Data publikacji | 2011-02-28 | 2012-02-28 | 2013-02-28 | 2014-02-28 | 2015-02-26 | 2016-02-25 | 2017-02-22 | 2018-02-27 | 2019-02-27 | 2020-02-25 | 2021-02-25 | 2022-03-01 | 2023-02-28 | 2024-03-05 | |
Przychody ze sprzedaży | 138 959 006 | 161 336 870 r/r +16.10% k/k +33.79% | 162 546 832 r/r +0.75% k/k +32.16% | 166 539 110 r/r +2.46% k/k +30.49% | 180 035 290 r/r +8.10% k/k +38.20% | 197 409 726 r/r +9.65% k/k +33.05% | 206 906 056 r/r +4.81% k/k +37.30% | 146 044 064 r/r -29.42% k/k +28.29% | 170 219 800 r/r +16.55% k/k +39.71% | 185 436 383 r/r +8.94% k/k +29.29% | 191 052 720 r/r +3.03% k/k +34.39% | 202 746 151 r/r +6.12% k/k +32.76% | 237 960 836 r/r +17.37% k/k +26.14% | 207 125 676 r/r -12.96% k/k +24.90% | |
Techniczny koszt wytworzenia produkcji sprzedanej | 67 733 011 | 79 391 980 r/r +17.21% k/k +36.01% | 77 917 004 r/r -1.86% k/k +32.65% | 80 936 755 r/r +3.88% k/k +33.01% | 86 379 772 r/r +6.73% k/k +39.42% | 90 164 817 r/r +4.38% k/k +35.11% | 89 785 080 r/r -0.42% k/k +39.75% | 47 473 184 r/r -47.13% k/k +32.18% | 73 143 000 r/r +54.07% k/k +56.70% | 75 004 961 r/r +2.55% k/k +36.19% | 88 318 042 r/r +17.75% k/k +26.12% | 77 343 510 r/r -12.43% k/k +27.14% | 93 193 003 r/r +20.49% k/k +26.71% | 85 868 652 r/r -7.86% k/k +21.36% | |
Koszty sprzedaży | 34 862 521 | 39 565 694 r/r +13.49% k/k +37.76% | 40 828 853 r/r +3.19% k/k +36.26% | 42 765 926 r/r +4.74% k/k +30.32% | 46 962 021 r/r +9.81% k/k +45.22% | 52 701 971 r/r +12.22% k/k +37.79% | 55 184 976 r/r +4.71% k/k +43.20% | 46 363 724 r/r -15.98% k/k +33.79% | 54 829 300 r/r +18.26% k/k +52.31% | 53 184 407 r/r -3.00% k/k +31.18% | 60 236 984 r/r +13.26% k/k +30.13% | 56 862 382 r/r -5.60% k/k +38.56% | 66 052 552 r/r +16.16% k/k +30.70% | 54 271 736 r/r -17.84% k/k +21.41% | |
Koszty ogólnego zarządu | 18 613 410 | 20 516 036 r/r +10.22% k/k +36.43% | 19 946 328 r/r -2.78% k/k +35.47% | 21 225 370 r/r +6.41% k/k +37.58% | 22 654 125 r/r +6.73% k/k +42.93% | 27 184 109 r/r +20.00% k/k +40.86% | 30 622 928 r/r +12.65% k/k +44.23% | 27 235 977 r/r -11.06% k/k +34.25% | 34 288 200 r/r +25.89% k/k +50.58% | 37 930 460 r/r +10.62% k/k +28.03% | 46 171 074 r/r +21.73% k/k +26.70% | 38 515 376 r/r -16.58% k/k +26.42% | 44 131 959 r/r +14.58% k/k +28.07% | 34 018 752 r/r -22.92% k/k +22.33% | |
Zysk ze sprzedaży | 17 750 065 | 21 863 160 r/r +23.17% k/k +18.46% | 23 854 647 r/r +9.11% k/k +21.92% | 21 611 059 r/r -9.41% k/k +16.62% | 24 039 372 r/r +11.24% k/k +19.42% | 27 358 830 r/r +13.81% k/k +13.56% | 31 313 072 r/r +14.45% k/k +17.35% | 24 971 178 r/r -20.25% k/k +8.64% | 7 959 300 r/r -68.13% k/k -51.44% | 19 316 556 r/r +142.69% k/k +6.19% | -3 673 381 r/r -119.02% k/k +65.32% | 30 024 883 r/r +917.36% k/k +47.36% | 34 583 323 r/r +15.18% k/k +14.88% | 32 966 536 r/r -4.68% k/k +46.03% | |
Pozostałe przychody operacyjne | 2 827 654 | 3 794 031 r/r +34.18% k/k +50.10% | 4 427 521 r/r +16.70% k/k +128.99% | 3 678 566 r/r -16.92% k/k +33.40% | 3 051 807 r/r -17.04% k/k +76.97% | 4 730 265 r/r +55.00% k/k +74.37% | 3 972 752 r/r -16.01% k/k +63.07% | 3 603 658 r/r -9.29% k/k +32.96% | 21 745 100 r/r +503.42% k/k +11.79% | 6 966 906 r/r -67.96% k/k +34.77% | 7 106 792 r/r +2.01% k/k +22.46% | 6 899 100 r/r -2.92% k/k +24.10% | 14 252 606 r/r +106.59% k/k +85.12% | 8 248 156 r/r -42.13% k/k +61.17% | |
Pozostałe koszty operacyjne | 9 766 100 | 7 331 888 r/r -24.93% k/k +34.37% | 12 092 896 r/r +64.94% k/k +46.91% | 4 827 341 r/r -60.08% k/k +48.69% | 3 622 955 r/r -24.95% k/k +200.23% | 5 454 720 r/r +50.56% k/k +31.05% | 4 132 016 r/r -24.25% k/k +91.65% | 3 954 013 r/r -4.31% k/k +33.96% | 12 874 200 r/r +225.60% k/k +881.77% | 17 723 877 r/r +37.67% k/k +161.79% | 78 050 112 r/r +340.37% k/k +3.70% | 21 502 195 r/r -72.45% k/k +8.80% | 15 950 350 r/r -25.82% k/k +50.04% | 38 553 716 r/r +141.71% k/k +10.14% | |
Zysk operacyjny (EBIT) | 10 811 619 | 18 325 303 r/r +69.50% k/k +18.02% | 16 189 272 r/r -11.66% k/k +22.03% | 20 462 285 r/r +26.39% k/k +13.42% | 23 468 224 r/r +14.69% k/k +13.66% | 26 634 375 r/r +13.49% k/k +17.63% | 31 153 808 r/r +16.97% k/k +15.54% | 24 620 823 r/r -20.97% k/k +8.25% | 16 830 200 r/r -31.64% k/k -51.26% | 8 559 585 r/r -49.14% k/k -48.40% | -74 616 701 r/r -971.73% k/k +6.79% | 15 421 788 r/r +120.67% k/k +149.91% | 32 885 579 r/r +113.24% k/k +21.02% | 2 660 976 r/r -91.91% k/k +136.40% | |
Przychody finansowe | 1 520 755 | 2 588 245 r/r +70.19% k/k +51.61% | 2 052 276 r/r -20.71% k/k +56.39% | 1 613 261 r/r -21.39% k/k +77.97% | 1 461 969 r/r -9.38% k/k +35.71% | 1 581 017 r/r +8.14% k/k +189.15% | 668 024 r/r -57.75% k/k +37.10% | 1 205 390 r/r +80.44% k/k +29.51% | 3 913 000 r/r +224.63% k/k +33.93% | 2 022 788 r/r -48.31% k/k +47.76% | 4 084 098 r/r +101.90% k/k +89.94% | 2 419 284 r/r -40.76% k/k +30.88% | 2 110 455 r/r -12.77% k/k +118.88% | 2 613 148 r/r +23.82% k/k +60.15% | |
Koszty finansowe | 5 294 921 | 5 861 094 r/r +10.69% k/k +38.12% | 4 775 018 r/r -18.53% k/k +39.18% | 4 561 920 r/r -4.46% k/k +27.89% | 5 587 875 r/r +22.49% k/k +51.90% | 5 825 471 r/r +4.25% k/k +42.28% | 5 662 720 r/r -2.79% k/k +31.46% | 6 819 422 r/r +20.43% k/k +25.20% | 11 068 200 r/r +62.30% k/k +58.39% | 8 278 524 r/r -25.20% k/k +33.39% | 8 629 676 r/r +4.24% k/k +41.74% | 8 656 071 r/r +0.31% k/k +52.15% | 12 390 716 r/r +43.14% k/k +35.56% | 11 617 856 r/r -6.24% k/k +30.53% | |
Pozostałe przychody (koszty) | -221 777 | -198 756 r/r +10.38% k/k -36.54% | -188 057 r/r +5.38% k/k -26.98% | -66 355 r/r +64.72% k/k -31.15% | -55 410 r/r +16.50% k/k -20.64% | -38 354 r/r +30.78% k/k -126.22% | -115 024 r/r -199.90% k/k -56.91% | 83 418 r/r +172.52% k/k +196.79% | 292 400 r/r +250.52% k/k -16.52% | 681 360 r/r +133.02% k/k -10.98% | -443 021 r/r -165.02% k/k -43.92% | 225 371 r/r +150.87% k/k +5.75% | -703 485 r/r -412.15% k/k -43.03% | -704 376 r/r -0.13% k/k -26.62% | |
Zysk z działalności gospodarczej | 6 815 676 | 14 853 698 r/r +117.93% k/k +15.63% | 13 278 474 r/r -10.60% k/k +20.71% | 17 447 270 r/r +31.40% k/k +13.81% | 19 286 908 r/r +10.54% k/k +7.15% | 22 351 568 r/r +15.89% k/k +17.16% | 26 044 088 r/r +16.52% k/k +12.90% | 19 090 209 r/r -26.70% k/k +5.23% | 9 967 400 r/r -47.79% k/k -67.65% | 2 985 209 r/r -70.05% k/k -76.15% | -79 605 300 r/r -2766.66% k/k +5.57% | 9 410 372 r/r +111.82% k/k +269.98% | 21 901 833 r/r +132.74% k/k +18.35% | -7 048 108 r/r -132.18% k/k +53.43% | |
Wynik zdarzeń nadzwyczajnych | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Zysk przed opodatkowaniem | 6 815 676 | 14 853 698 r/r +117.93% k/k +15.63% | 13 278 474 r/r -10.60% k/k +20.71% | 17 447 270 r/r +31.40% k/k +13.81% | 19 286 908 r/r +10.54% k/k +7.15% | 22 351 568 r/r +15.89% k/k +17.16% | 26 044 088 r/r +16.52% k/k +12.90% | 19 090 209 r/r -26.70% k/k +5.23% | 9 967 400 r/r -47.79% k/k -67.65% | 2 985 209 r/r -70.05% k/k -76.15% | -79 605 300 r/r -2766.66% k/k +5.57% | 9 410 372 r/r +111.82% k/k +269.98% | 21 901 833 r/r +132.74% k/k +18.35% | -7 048 108 r/r -132.18% k/k +53.43% | |
Zysk (strata) netto z działalności zaniechanej | 0 | 0 | 0 | 0 | 0 k/k -100.00% | 0 k/k -100.00% | 1 185 632 k/k +53.61% | 20 212 181 r/r +1604.76% k/k +1.35% | 0 r/r -100.00% k/k -100.00% | 7 239 450 k/k +625.99% | 23 415 495 r/r +223.44% k/k +0.46% | 0 r/r -100.00% | 0 | 0 | |
Zysk netto | 5 187 993 | 10 918 330 r/r +110.45% k/k +19.28% | 10 204 147 r/r -6.54% k/k +19.02% | 13 212 979 r/r +29.49% k/k +14.21% | 14 675 099 r/r +11.07% k/k +9.39% | 17 463 627 r/r +19.00% k/k +17.22% | 21 350 224 r/r +22.26% k/k +14.64% | 33 759 265 r/r +58.12% k/k -1.38% | 7 357 300 r/r -78.21% k/k -69.53% | 17 502 435 r/r +137.89% k/k +49.04% | -48 395 408 r/r -376.51% k/k +0.99% | 4 700 587 r/r +109.71% k/k +785.55% | 19 538 123 r/r +315.65% k/k +12.79% | -12 791 816 r/r -165.47% k/k +35.59% | |
Zysk netto akcjonariuszy jednostki dominującej | 5 152 350 | 10 909 496 r/r +111.74% k/k +19.30% | 9 999 737 r/r -8.34% k/k +17.32% | 13 225 421 r/r +32.26% k/k +14.73% | 14 602 640 r/r +10.41% k/k +9.22% | 17 514 765 r/r +19.94% k/k +18.16% | 20 045 144 r/r +14.45% k/k +13.99% | 30 597 722 r/r +52.64% k/k -1.21% | 7 288 500 r/r -76.18% k/k -69.74% | 17 421 524 r/r +139.03% k/k +48.80% | -48 436 941 r/r -378.03% k/k +0.95% | 4 599 400 r/r +109.50% k/k +716.63% | 19 463 085 r/r +323.17% k/k +12.93% | -12 787 468 r/r -165.70% k/k +35.52% | |
EBITDA | 24 894 446 | 30 555 422 r/r +22.74% k/k +25.87% | 28 290 344 r/r -7.41% k/k +24.58% | 32 472 576 r/r +14.78% k/k +20.40% | 35 982 337 r/r +10.81% k/k +23.50% | 40 837 955 r/r +13.49% k/k +24.84% | 47 712 840 r/r +16.83% k/k +24.73% | 35 715 417 r/r -25.15% k/k +16.69% | 44 143 800 r/r +23.60% k/k +1.64% | 31 414 955 r/r -28.83% k/k -4.89% | -13 429 068 r/r -142.75% k/k +39.87% | 29 477 555 r/r +319.51% k/k +36.01% | 63 383 999 r/r +115.02% k/k +27.12% | 46 227 936 r/r -27.07% k/k +24.87% |
Dane kwartalne RZiS oraz CashFlow obliczne są na podstawie publikowanych danych skumulowanych.
Dynamika zmian dla sektora obliczana jest w oparciu o medianę.
Dane w tys. PLN
Informacje
ISIN: | DE000BAY0017 |
---|---|
Liczba akcji: | 826 950 000 |
Kapitalizacja: | 100 887 900 000 |
Enterprise Value: | 285 009 870 000 |
Branża: | Produkcja leków |
Bayer AG to firma naukowo-medyczna. Segmenty Spółki to: farmaceutyki, zdrowie konsumentów, uprawa roślin i zdrowie zwierząt. Segment Pharmaceuticals... Bayer AG to firma naukowo-medyczna. Segmenty Spółki to: farmaceutyki, zdrowie konsumentów, uprawa roślin i zdrowie zwierząt. Segment Pharmaceuticals koncentruje się na badaniach, opracowywaniu i sprzedaży produktów na receptę i specjalistycznych terapii, szczególnie w dziedzinie kardiologii, onkologii, ginekologii, hematologii i okulistyki, a także radiofarmakologii i innych. Segment Consumer Health opracowuje, produkuje i sprzedaje bez recepty produkty dostępne bez recepty w zakresie m.in. dermatologii, suplementów diety, leków przeciwbólowych, przewodu pokarmowego, przeziębienia, alergii, zatok i grypy, pielęgnacji stóp i ochrony przeciwsłonecznej. Segment Crop Science bada, rozwija i wprowadza na rynek rozwiązania i nasiona do ochrony roślin, a także obejmuje spółkę zależną Monsanto. Segment Animal Health zajmuje się opracowywaniem, produkcją i marketingiem weterynaryjnych produktów na receptę i bez recepty.
Nazwa: | BAYER AG |
---|---|
Adres: | Werk Leverkusen, 51-368, Leverkusen, Deutschland |
CEO: | Bill Anderson |
Telefon: | +49 (0) 214 30-1 |
WWW: | http://www.bayer.com/ |